Results 171 to 180 of about 718,683 (284)

The effect of PARP inhibitor-based targeted therapy on BRCA-mutated ovarian cancer: systematic literature review. [PDF]

Front Oncol
Panjarwanto DA, Nabila P, Octavia L, Indrawan IWA, Utomo RP, Permana AY, Kaspan, Adnyana IGHE, Javier RM, Akbar MZH.   +9 more
europepmc   +1 more source

Liquid biopsy in genitourinary oncology: Current clinical applications and future prospects across prostate, bladder, and renal cancers

UroPrecision, EarlyView.
Abstract Liquid biopsy has emerged as a transformative approach in oncology, providing minimally invasive access to tumor‐derived biomarkers with applications across diagnosis, prognosis, therapeutic guidance, and disease monitoring. This literature review synthesizes evidence from 125 studies evaluating circulating tumor DNA, circulating tumor cells ...
Kirolos Eskandar
wiley   +1 more source

LIPT1 loss confers replication stress and PARP inhibitor sensitivity through PrimPol-mediated ssDNA gaps. [PDF]

Sci Adv
Shang Z, Chiang JC, Hsu CC, Newman C, Davis AJ, Zhang Y.   +5 more
europepmc   +1 more source

Inhibition of HMGA2 Leads to Reduced Cell Proliferation and Increased Apoptosis in Human Embryonal Carcinoma Cell Lines

Andrology, EarlyView.
ABSTRACT Background The most prevalent solid tumors in young men are testicular germ cell tumors (TGCTs), and embryonal carcinoma is the most common subtype among non‐seminomatous germ cell tumors (NSGCTs). Despite the excellent cure rates of cisplatin‐based chemotherapy, resistance develops in 15%–30% of patients with metastatic cancer, which results ...
Marco De Martino, Matteo Lampitto, Alfredo Fusco, Marco Barchi, Francesco Esposito, Paolo Chieffi   +5 more
wiley   +1 more source

Randomized phase 2 trial of a PARP inhibitor TSL-1502 in germline BRCA-mutated, HER2-negative locally advanced/metastatic breast cancer. [PDF]

Signal Transduct Target Ther
Lan B, Xu F, Sun T, Qiu F, Wang Y, Wang S, Li W, Zhong Y, Wu X, Ouyang Q, Wang K, Mi X, Liu R, Xu B.   +13 more
europepmc   +1 more source

Chemotherapy resistance and risk stratification in gestational trophoblastic neoplasia: A systematic review and network meta‐analysis

Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
Higher pretreatment β‐hCG, greater tumor burden, higher FIGO stage/score, and choriocarcinoma were associated with higher chemoresistance risk in gestational trophoblastic neoplasia. In exploratory network analyses, etoposide‐containing regimens showed lower predicted chemoresistance.
Ying‐Ying Xue, Xin‐Yue Yang, Fang‐Yu Chen, Hui‐Ting Yang, Chao Zhang, Jin‐Zhu Yan, Shi‐Shi Wu, Long Wang   +7 more
wiley   +1 more source

BET inhibition disrupts the FOXM1-MYC axis to induce BRCAness and enhance PARP inhibitor response. [PDF]

NPJ Precis Oncol
Fang P, Saunders A, Minn K, Chua KJ, Brooks RA, Bakke D, Leiserowitz GS, Johnson N, Wang S, Chien J.   +9 more
europepmc   +1 more source

CD47 promotes myeloma cell growth through JAK–STAT3/MYC signalling and is targetable by ruxolitinib

British Journal of Haematology, EarlyView.
Summary Cluster of differentiation 47 (CD47), a ‘don't eat me’ immune checkpoint receptor, is frequently overexpressed on multiple myeloma (MM) cells and contributes to immune evasion. While its immune regulatory function is well established, the intrinsic oncogenic role of CD47 remains poorly understood.
Omar Faruq, Deepak Iyer, Patrick Wang, Mariusz Shrestha, Cuihong Wei, Aaron D. Schimmer, Hong Chang   +6 more
wiley   +1 more source

CRISPR screen identifies autophagy inhibition (GNS561) as a PARP inhibitor (AZD5305) combination strategy in small cell lung cancer. [PDF]

Cancer Metab
Yu T, Barayan R, Song L, Venkatasubramanian V, Tamakuwala J, Nair SN, Philip V, Lok BH.   +7 more
europepmc   +1 more source

Overexpression of the ERG oncogene in prostate cancer identifies candidates for PARP inhibitor-based radiosensitization. [PDF]

J Clin Invest
Köcher S, Elsesy ME, Moustafa A, Mohammadi W, Perugachi Heinsohn A, Nagaraj Y, Oh-Hohenhorst SJ, Hahn J, Siebels B, Mair T, Burdak-Rothkamm S, Tennstedt P, Simon R, Lange T, Tilki D, Frenzel T, Maurer T, Petersen C, Schlüter H, Bokemeyer C, von Amsberg G, Rothkamm K, Mansour WY.   +22 more
europepmc   +1 more source